The Vanguard Group, Inc. recently announced the acquisition of new stake in Inovio Pharmaceuticals Inc (NASDAQ:INO). The institutional investor has increased its shareholding in the Healthcare company by 0.03% to 19.98 million shares with purchase of 6949.0 shares. This fresh investment now brings its stake to 7.32% valued currently at $10.19 million.
With over 11.18 million Inovio Pharmaceuticals Inc (INO) shares trading Friday and a closing price of $0.77 on the day, the dollar volume was approximately $8.61 million. The shares have shown a positive half year performance of 46.67% and its price on 01/12/24 lost nearly -12.99%. Currently, there are 272.99M common shares owned by the public and among those 268.63M shares have been available to trade.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 4 analysts who have offered their price forecasts for INO have a consensus price objective of $0.70. The analysts have set the share’s price value over the next 12 months at a high of $1.00 and a low of $0.40. The average price target is -10.0% below its recent price level and a downside to the estimated low will see the stock lose -92.5% over that period. But an upside of 23.0% will see the stock hit the forecast high price target while median target price for the stock is $0.70.
Insiders at the company have transacted a total of 35 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 22 of these insider trades were purchases, accounting for 692,311 shares. Insider sales of the common stock occurred on 13 occasions, with total insider shares sold totaling 241,286 shares.
The top 3 mutual fund holders in Inovio Pharmaceuticals Inc are Vanguard Total Stock Market ETF, Vanguard Strategic Small Cap Equi, and Vanguard Extended Market Index Fu. Vanguard Total Stock Market ETF owns 8.26 million shares of the company’s stock, all valued at over $4.21 million. Vanguard Extended Market Index Fu bought 47601.0 shares to bring its total holdings to over 3.47 million shares at a value of $1.77 million. Vanguard Extended Market Index Fu now owns shares totaling to 1.27% of the shares outstanding.
Shares of Inovio Pharmaceuticals Inc (NASDAQ: INO) opened at $0.875, down -$0.01 from a prior closing price of $0.88. However, the script later moved the day high at 0.8900, down -12.99%. The company’s stock has a 5-day price change of 6.94% and 45.28% over the past three months. INO shares are trading 50.98% year to date (YTD), with the 12-month market performance down to -55.49% lower. It has a 12-month low price of $0.32 and touched a high of $1.99 over the same period. INO has an average intraday trading volume of 3.49 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 40.60%, 70.31%, and 45.77% respectively.
Institutional ownership of Inovio Pharmaceuticals Inc (NASDAQ: INO) shares accounts for 20.37% of the company’s 272.99M shares outstanding. Mutual fund holders own 10.50%, while other institutional holders and individual stakeholders account for 9.86% and 1.89% respectively.
It has a market capitalization of $210.20M and a beta (3y monthly) value of 0.83. The earnings-per-share (ttm) stands at -$0.63. Price movements for the stock have been influenced by the stock’s volatility, which stands at 16.72% over the week and 12.65% over the month.
Analysts forecast that Inovio Pharmaceuticals Inc (INO) will achieve an EPS of -$0.1 for the current quarter, -$0.07 for the next quarter and -$0.3 for 2024. The lowest estimate earnings-per-share for the quarter is -$0.15 while analysts give the company a high EPS estimate of -$0.08. Comparatively, EPS for the current quarter was -$0.21 a year ago. Earnings per share for the fiscal year are expected to increase by 55.98%, and 40.78% over the next financial year. EPS should grow at an annualized rate of 41.50% over the next five years, compared to -1.47% over the past 5-year period.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 4 brokerage firm advisors rate Inovio Pharmaceuticals Inc (INO) as a “Moderate Buy” at a consensus score of 2.50. Specifically, 1 Wall Street analysts polled rate the stock as a buy, while 3 of the 4 advise that investors “hold,” and 0 rated it as a “Sell.”
